文献速递免疫规划卫生政策与健康促进

加纳北部PCV13引入后肺炎球菌性脑膜炎与肺炎的经济负担估计

Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction.
PubMed 文献 · Vaccine · 2021-07-01

该研究在加纳北部(非洲脑膜炎带)PCV13纳入婴儿免疫规划后,通过横断面调查和模型估计肺炎球菌性脑膜炎与肺炎的经济负担。结果显示典型年份PCV13型肺炎和脑膜炎分别约6441例和286例,年经济负担约523万美元(每例777美元),其中78.0-93.4%为死亡相关间接成本。结论认为疾病负担仍显著,尤其在大龄儿童和成人中。

要点

  • PCV13型肺炎每例成本:<5岁423美元,5-14岁911美元,≥15岁784美元。
  • PCV13型脑膜炎每例成本:<5岁2128美元,5-14岁3247美元,≥15岁2883美元。
  • 总社会成本中78.0-93.4%由PCV13型疾病死亡相关间接成本构成。

核心结论

  • 加纳北部PCV13型肺炎球菌疾病的经济负担仍然显著,尤其在大龄儿童和成人中。

研究设计与样本

  • 在加纳北部三家医院对肺炎或脑膜炎患者进行横断面调查,收集家庭、门诊和住院的直接医疗与非医疗成本及间接成本。
  • 肺炎负担基于2017-2018年行政记录估计,肺炎球菌性脑膜炎负担基于2017-2018年病例监测数据估计。
  • 经济负担从社会视角以2019年美元报告,模型覆盖总人口5,068,521的区域。

主要发现

  • 模型估计PCV13引入后典型年份发生6,441例PCV13型肺炎和286例PCV13型脑膜炎。
  • 基础情景下年总经济负担为5,230,035美元,每例777美元。
  • PCV13型肺炎每例成本:<5岁423美元,5-14岁911美元,≥15岁784美元。
  • PCV13型脑膜炎每例成本:<5岁2,128美元,5-14岁3,247美元,≥15岁2,883美元。
  • 总社会成本的78.0-93.4%来自PCV13型疾病死亡相关间接成本。

临床怎么用

  • 提示在婴儿PCV13免疫规划基础上,可能需要调整婴儿免疫程序、开展应急接种或补种PCV13以控制剩余疫苗型疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ghana introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine infant immunization program in 2012, using a three-dose primary series without a booster. Despite ≥ 88% reported three-dose vaccination coverage since 2013, PCV13-type pneumococcal meningitis outbreaks have occurred. We estimated the ongoing economic burden of PCV13-type pneumococcal meningitis and pneumonia in northern Ghana, an area within the African meningitis belt with seasonal increases of pneumococcal meningitis post-PCV13 introduction, to inform PCV13 vaccination policy. METHODS: We performed a cross-sectional survey among patients with pneumonia or meningitis at three hospitals in northern Ghana to determine patient-level costs (direct medical and nonmedical, indirect patient and caregiver costs) incurred in household, outpatient, and inpatient settings. Pneumonia burden was estimated using 2017-2018 administrative records. Pneumococcal meningitis burden was estimated using 2017-2018 case-based surveillance data. Economic burden was reported in 2019 U.S. dollars ($) from the societal perspective. RESULTS: For an area with a total population of 5,068,521, our model estimated 6,441 PCV13-type pneumonia cases and 286 PCV13-type meningitis cases occurred in a typical year post-PCV13. In the base case scenario, the total economic burden was $5,230,035 per year ($777 per case). By age group, cost per PCV13-type pneumonia case was $423 (<5 years), $911 (5-14 years), and $784 (≥15 years); cost per PCV13-type meningitis case was $2,128 (<5 years), $3,247 (5-14 years), and $2,883 (≥15 years). Most (78.0-93.4%) of the total societal cost was due to indirect costs related to deaths from PCV13-type diseases. CONCLUSIONS: The estimated economic burden of PCV13-type disease in northern Ghana remains substantial, especially in older children and adults who were expected to have benefited from indirect effects from infant immunization. Additional interventions such as changes in the infant immunization schedule, reactive vaccination, or catch-up PCV13 vaccination may be needed to control remaining vaccine-type disease.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kobayashi M, Abdul-Karim A, Milucky JL, et al. Estimating the economic burden of pneumococcal meningitis and pneumonia in northern Ghana in the African meningitis belt post-PCV13 introduction. Vaccine. 2021. PMID: 34218962. doi:10.1016/j.vaccine.2021.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。